WO2024184797 - FORMULATION AND METHOD OF PREVENTING OR TREATING HYPOCALCAEMIA
National phase entry is expected:
Publication Number
WO/2024/184797
Publication Date
12.09.2024
International Application No.
PCT/IB2024/052091
International Filing Date
04.03.2024
Title **
[English]
FORMULATION AND METHOD OF PREVENTING OR TREATING HYPOCALCAEMIA
[French]
FORMULATION ET MÉTHODE DE PRÉVENTION OU DE TRAITEMENT DE L'HYPOCALCÉMIE
Applicants **
WELFARE CONCEPTS LIMITED
301r Botany Road
Golflands
Auckland, 2013, NZ
Inventors
BHUSAL, Prabhat
301r Botany Road
Golflands
Auckland, 2013, NZ
WALKER, Greg
301r Botany Road
Golflands
Auckland, 2013, NZ
WAPENAAR, Wendela
301r Botany Road
Golflands
Auckland, 2013, NZ
WEBB, Laura
301r Botany Road
Golflands
Auckland, 2013, NZ
OLDE RIEKERINK, Richard Gerhardus Martinus
301r Botany Road
Golflands
Auckland, 2013, NZ
TUCKER, Ian George
301r Botany Road
Golflands
Auckland, 2013, NZ
Priority Data
2023900581
06.03.2023
AU
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| * | |
International Searching Authority |
IP Australia
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Translation |
|
Recalculate
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing | 1869 | |
| EPO | Filing, Examination | 14148 | |
| Japan | Filing | 538 | |
| South Korea | Filing | 575 | |
| USA | Filing, Examination | 7835 |
Total: 24965 USD
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Abstract[English]
A controlled-release Vitamin D3 formulation that provides both an initial burst release as well as sustained release of an active form of Vitamin D3, and its use in preventing or treating conditions such as hypocalcaemia.[French]
L'invention concerne une formulation de vitamine D3 à libération contrôlée, qui fournit à la fois une libération en rafale initiale ainsi qu'une libération prolongée d'une forme active de vitamine D3, ainsi que son utilisation dans la prévention ou le traitement de pathologies telles que l'hypocalcémie.